abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
Shire pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shire drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
idursulfase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Heparan sulfate.
- Target
- Heparan sulfate
- Mechanism
- Heparan sulfate hydrolytic enzyme
-
Development asset linked to Shire in public FDA and regional records.
-
Development asset linked to Shire in public FDA and regional records.
-
maribavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Serine/threonine protein kinase UL97.
- Target
- Serine/threonine protein kinase UL97
- Mechanism
- Phosphotransferase pUL97 inhibitor
-
Development asset linked to Shire in public FDA and regional records.
-
Development asset linked to Shire in public FDA and regional records.
-
velaglucerase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Glucocerebroside.
- Target
- Glucocerebroside
- Mechanism
- Glucocerebroside hydrolytic enzyme